complications make early delivery a possibility.3 Delivery before maturation of the fetal lungs may result in life-threatening respiratory distress syndrome (RDS) caused by inadequate production of surfactant by type II pneumocytes of the lung. In 1971 Gluck et al. reported the first fetal lung maturity test using amniotic fluid, the lecithinlsphingomyelin (L/S) ratio [1] . Although widely utilized as a predictor of lung maturation, a major drawback of the L/S ratio is the length of time and technical expertise required to complete the thin-layer chromatographic procedures typically utilized for separation and visualization of the lipids. Because of these limitations, other methods for assessing pulmonary maturity with amniotic fluid have been developed.
Examples include a rapid phosphatidylglycerol (PG) assay (AmnioStat-FLM) [2] , the foam stability index (FSI) [3] , optical absorbance [4] [5] [6] , lamellar body number density [7] , and fluorescence polarization [8] [9] [10] [11] . These tests were developed to provide more rapid and reliable alternatives to L/S ratio determination by thin-layer chromatography (TLC (1), and fetal teratoma (1). Some patients had more than one complication.
The samples were assayed immediately or after storage at -70 #{176}C and were only used for the RIMAD study after completion of clinical testing. Eighty-six samples were obtained within 72 h of delivery. The use of amniotic fluid samples in our study was in accordance with the guidelines established by the Committee on the Protection of the Rights of Human Subjects at our institution.
RIMAD

ASSAY
We performed the RIMAD assay according to the method of Dubin [12] with slight modification.
Each amniotic fluid sample was filtered through a 13-mm glass filter with a pore size of 39 .tm (Abbott Labs., Abbott Park, IL) before analysis or storage at -70 #{176}C. These filters are designed to remove large cellular debris and particulate matter but allow small cells and lamellar bodies to pass through. We mixed 600 tL of amniotic fluid with an equal volume of distilled water, and another 600 j.L was mixed with an equal volume of glycerol (Sigma, St. Louis, MO). The samples were vortex-mixed for 20 s at setting 5 with a Vortex Genie (Fisher Scientific, Fair Lawn, NJ), then immediately transferred to 1-mL quartz cuvettes. The sample diluted in glycerol (A2) was placed in the reference holder of a Hitachi dual-beam spectrophotometer (model U-32 10), and the sample diluted in distilled water (A1) was placed in the sample holder. The absorbance was read from 350 rim to 750 nm and the difference reading at 650 nm (A1 -A2)650, or A650, was recorded.
The precision study was conducted with a control pool of amniotic fluid that was analyzed twice a day for 10 days. Both our L/S ratio analysis (mean = 2.78) and RIMAD analysis of this sample (mean = 0.05 7) indicated maturity. The mean, CV, and total, between-day, and within-run SDs were calculated.
To determine the effect on RIMAD assay performance of storage of amniotic fluid at -70 #{176}C, fresh amniotic fluid samples were filtered and divided into two aliquots; one was analyzed immediately and the other was frozen at -70 #{176}C for 7 days. All frozen samples were thawed to room temperature and vortexmixed for 1 mm before dilution.
The statistical differences between fresh and frozen samples were determined by calculating (a) 95% elliptical confidence limits for slope and intercept derived from linear least-squares regression analysis and (b) the paired t-test on sample means. Our results indicated no significant difference between values derived from fresh or frozen samples (n = 22) by regression studies or the paired t-test (P = 0.887).
INTERFERENCE
Hemolysate, prepared from heparin-treated whole blood, was added to control pools of amniotic fluid to achieve specific concentrations of hemoglobin. The hemolysate was centrifuged for 30 mm at 1300g to remove cell stroma and other cell debris. The control concentrations for the hemoglobin interference study were M650 = 0.056 and 0.092. The absorbance was measured and compared with an amniotic fluid without hemoglobin. To closely approximate endogenous bilirubin, we added icteric serum (333 mg/L) to an amniotic fluid control pool 0.07 5). To correct for dilution and the effect of serum, we added normal serum (9.0 mgIL bilirubin) to another control pool. (This resulted in bilirubin concentrations of 0.015 mg/L to 0.3 mgfL.) Percent interference was calculated using the results from the amniotic fluid with normal serum as a baseline. The effects of whole blood on RIMAD assay performance were determined by addition of heparin-treated whole blood to control pools of amniotic fluid (pool 1 M650 = 0.056; pool 2 1A650 = 0.081). The hematocrit was determined to add specific volumes of erythrocytes to the amniotic fluid.
CORRELATION STUDIES
The RIMAD assay was performed on all 173 samples, although the L/S ratio (including quantification of PG), FSI, TDx-FLM (Abbott Labs.), and AmnioStat-FLM (Irvine Scientific, Santa Aria, CA) were performed on subgroups of various sizes according to the physician's orders. These additional assays were performed on the basis of previously published methods or according to the manufacturer's instructions [1, [13] [14] [15] [16] [17] and allowed us to compare the RIMAD assay with established methods. The decision points for maturity by the other FLM tests were: L/S ratio, 2; FSI, 48; and TDx-FLM, 30 mg surfactantlg albumin. Our use of 30 mg/g albumin as the lowest mature decision point for the TDx-FLM test, instead of 50 mg/g albumin as recommended by the manufacturer, was based on the superior discriminating ability of the former as demonstrated in a previous study [18] . To allow statistical comparison of predictive value (PV) and efficiency calculations on data subsets with variable prevalence, the data for these calculations were normalized to n = 86 samples for a 9.3% prevalence of RDS.
CLINICAL EVALUATION
The respiratory outcomes were determined by review of the neonate's hospital records. The diagnosis of RDS was made by
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::: [18] . For RIMAD and comparative methods, only those samples obtained within 72 h of delivery and with a documented outcome were included in the referent value analysis, PV calculations, and ROC analyses. PV analysis was conducted according to the definitions in Table 1 .
STATISTICAL ANALYSIS
The statistical analysis was performed using the Predictive Value Calculator Software (Helena Labs., Beaumont, TX), LabStat Version 2.3 (Prism Assoc.) and Inplot Software (GraphPad). ROC analyses were performed on results for FSI, gestational age (GA), L/S ratio, RIMAD, and TDx-FLM measurements by using a spreadsheet program based on the statistical methods described by Hanley and McNeil [19, 20] .
Results
ANALYTICAL EVALUATION
Our analytical evaluation of the RIMAD method included determination of assay precision, the effect of interfering chromogens, and the correlation with established FLM tests. A precision study was conducted by analysis of one concentration of control amniotic fluid (mean = 0.057) twice a day for served for the high pool (M650 = 0.092) was 8%. Negative interference was observed in the low pool (M650 = 0.056) with a maximum of 12%. Bilirubin interference was assessed at concentrations ranging from 0.6 mgfL to 11.0 mg/L (Fig. 1B) . The magnitude of the interference ranged from 0.9% to 5.2%. The effects of various amounts of whole blood at two lamellar body concentrations are shown in Fig. 1C . For the high amniotic fluid pool (M650 = 0.081), the initial effect of even small amounts of intact erythrocytes is to raise the apparent RIMAD significantly, whereas for the lower pool (M650 = 0.056), the initial effect is a significant lowering of the test results. The addition of as little as 2.5 .tL of intact erythrocytes per 3 mL of amniotic fluid was sufficient to produce a change in RIMADs in either pooi.
The RIMAD assay was compared with FLM methods currently in use in our laboratory by using linear least-squares regression analysis (Fig. 2) . The RIMAD assay correlated best with the FSI (r = 0.623, n = 145; Fig. 2B ). The correlation between the RIMAD assay and the TDx-FLM assay was similar, with a correlation coefficient of 0.600, n = 146, although the correlation for the L/S ratio was somewhat lower (r = 0.3 53, n = 81) ( Fig. 2A,C) . The weakest correlation was for GA (r = 0.272, n = 173). The GA of the samples ranged from 26 to 39 weeks and increasing age resulted in increasing scatter of the RIMAD data (Fig. 2D) .
CLINICAL EVALUATION
Of the 173 amniotic fluid samples available for study, 86 were collected within 72 h of delivery and RDS was diagnosed in 8 of these infants (9.3%). RIMADs (M650) for normal respiratory outcomes (n = 78) ranged from 0.018 to 0.471. RIMADs for RDS outcomes (n = 8) ranged from 0.004 to 0.03 6. Data for the referent value analysis of the RIMAD tests are shown in Table  3 Results of the statistical analysis for the area under the ROC curve for each FLM test and GA (Table 6 ) confirm that the area calculated for the RIMAD test was the highest (0.997). This area was not significantly different (P = 0.3 156) from that calculated for the TDx-FLM test (0.993). However, the data did demonstrate a significant difference between the area calculated for
RIIvIAD vs FSI (P = 0.017), the L/S ratio (P = 0.023), and GA (P = 0.012).
Discussion
Accurate and timely assessment of fetal lung development is necessary in patients at risk for delivery of premature infants who may develop life-threatening RDS. Since the report by Gluck et al.
[I] that lecithin concentration in amniotic fluid On the basis of our analytical and clinical evaluation, the RIMAD assay may satisfy most, if not all, of these criteria.
Our day-to-day imprecision (SD = AA651 0.004) for the R[1vIAD test compares reasonably well with that (SD = .A650 0.002) reported previously by Dubin [12] . Our total imprecision (CV) for RIMAD was 7.1% at a .A650 concentration just above our provisional cut point for maturity. This imprecision is somewhat greater than we typically experience for the TDx-FLM assay (CV = 2.3%), but less than we experience for the L/S ratio (CV = 10.7%), at corresponding mean control concentrations. Finally, although not evaluated in the present study, we believe that the analytical and clinical performance characteristics of the RTh'IAD assay may make it particularly well-suited for incorporation into a sequential testing approach such as the "fetal maturity cascade" [25] .
